-Basilea Pharmaceutica Ltd. reports today that Dr. Ingrid Heinze-Krauss will retire after 15 years with the company. Prior to joining Basilea, he held various positions with increasing responsibility at Hoechst Marion Roussel in Frankfurt, Germany and at Novartis Pharma AG in Basel, Switzerland.
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Bernick, Brian A.; Cacace, Janice Louise; Persicaner, Peter H.R.; Irani, Neda; Amadio, Julia M., filed on April 20, 2015, was made available online on August 20, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspo
By a News Reporter-Staff News Editor at Clinical Trials Week 60 Degrees Pharmaceuticals,, a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital announced that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever
Adocia and Eli Lilly and Company reported the initiation of a Phase 1 b clinical trial evaluating BioChaperone Lispro, an ultra- rapid formulation of insulin lispro licensed to Lilly. The formulation uses Adocia's proprietary technology BioChaperone, which is designed to accelerate insulin absorption. "This new clinical study aims to further docum
Adocia reported the initiation of a Phase I clinical trial evaluating a new and more concentrated formulation of BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Eli Lilly and Company. Our goal is to test the potential bioequivalence of these two formulations "says Olivier Soula, Adocia's R&D Director and Deputy General
The Alliance Foundation Trials, the Austrian Breast& Colorectal Cancer Study Group and Pfizer have launched the Palbociclib Collaborative Adjuvant Study, or PALLAS. The company said the global Phase 3 clinical trial for patients with early-stage breast cancer is being conducted in conjunction with Breast International Group, German Breast Group,...
Agile Therapeutics, Inc. a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that active recruitment has closed in its ongoing single-arm, open-label Phase 3 SECURE clinical trial of Twirla , its investigational contraceptive patch.
AGTC filed an Investigational New Drug application with the U.S. Food and Drug Administration in March to conduct a Phase I/II clinical trial of the company's gene therapy product candidate for the treatment of XLRS. Utilizing technology licensed from the University of Florida, AGTC's XLRS product candidate uses an AAV capsid with surface residues
DUBLIN, Aug. 31, 2015/ PRNewswire/ Allergan plc, a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of Naurex Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system, including depression. Allergan acquired
Amicus Therapeutics, a biotechnology company at the forefront of therapies for rare and orphan diseases, and Scioderm, Inc. a privately-held biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, have signed a definitive agreement under which Amicus will acquire 100% of the capital stock o
Asahi Kasei Pharma received rights to develop and market XIAFLEX in Japan through an agreement concluded in March 2011. After conducting a Phase III clinical trial in Japan, Asahi Kasei Pharma obtained approval for the manufacture and marketing on July 3, 2015. Manufactured and distributed by: Asahi Kasei Pharma Corp. Date of approval for manufactu
It was recently announced by Biotronik that patients with implantable cardioverter-defibrillators who need a magnetic resonance image scan can safely undergo the procedure thanks to a successful collaboration with leading Electrophysiologists. Clinical trial results were submitted to the U. S Food and Drug Administration and are awaiting approval..
SHAOXING, China, Aug. 31, 2015/ PRNewswire/ Ascletis today announced it received the approval from the Taiwan Food and Drug Administration to start phase II clinical trial for its all-oral interferon- free regimen to treat chronic hepatitis C. The regimen contains Ascletis' two direct-acting antiviral agents, the NS3/4A protease inhibitor ASC08 a
Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that the third patient was successfully dosed at Chicago- based Rush University Medical Center in a Phase 1/ 2 a clinical trial evaluating activity of escalating doses of AST-OPC1 in newly injured patients with sensory a
By a News Reporter-Staff News Editor at Clinical Trials Week Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announces the publication of key clinical data for the novel hypomethylating agent guadecitabine in the prestigious journal, The Lancet Oncology.
Atara Biotherapeutics, Inc., a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that it completed enrollment in its blinded, randomized, PINTA 745 Phase 2 clinical trial in End-Stage Renal Disease patients with Protein Energy Wasting. The company expects to report...
Audentes Therapeutics reported that AT001, an investigational product in development for the treatment of X-Linked Myotubular Myopathy, has been granted orphan designation by the US Food and Drug Administration and the European Medicines Agency. The FDA and EMA Orphan Drug programs provide orphan designation to drugs and biologics that are intended
Release date- 28082015- Basel, Switzerland,- Basilea Pharmaceutica Ltd. reports today that Dr. Ingrid Heinze-Krauss will retire after 15 years with the company. Prior to joining Basilea, he held various positions with increasing responsibility at Hoechst Marion Roussel in Frankfurt, Germany and at Novartis Pharma AG in Basel, Switzerland.
BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that its lead compound, Plinabulin, will be presented in two posters at the upcoming 16 th World Conference on Lung Cancer, which is hosted by the International Association for the Study of Lung
Bio-Path Holdings, Inc.,, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced the formation of its inaugural Scientific Advisory Board comprised of leading oncology experts. Jorge Cortes, M.D., renowned leukemia expert from The University of Texas MD Anderson Cancer Center, will join as
BioMarin Pharmaceutical Inc. announced today that the company will present data in two oral and 19 poster presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting which will be held on September 1-4 in Lyon, France. In an oral platform session, long-term efficacy and safety data from a Phase 2 extension study
BioTime, Inc. announced today that subsidiary Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, reported that the third patient was successfully dosed at Chicago- based Rush University Medical Center in a Phase 1/ 2 a clinical trial evaluating activity of escalating doses of AST-OPC1 in
By a News Reporter-Staff News Editor at Clinical Trials Week Cancer Research UK, the world's largest charitable funder of cancer research, will fund preclinical research evaluating the efficacy of Biothera's investigational cancer immunotherapy Imprime PGG in combination with monoclonal antibody therapies as a precursor to a phase 1-2 clinical
NEWTON, Mass. and JERUSALEM, Israel, Aug. 31, 2015/ PRNewswire/ Chiasma, Inc., a U.S. late-stage biopharmaceutical company developing octreotide capsules for the orphan condition acromegaly, today reported financial results for the second quarter ended June 30, 2015 and provided a corporate update. "In anticipation of the potential approval of o
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that patient enrollment has commenced in the Phase 2 clinical study of its investigational new drug Resunab? for the treatment of diffuse cutaneous systemic sclerosis.